Emergent BioSolutions | EBS - Дебиторская задолженность





Дебиторская задолженность Изменить Дата
Acadia Pharmaceuticals USD 166.33M 17.95M 2026-06
Akebia Therapeutics USD 47.03M 19.19M 2025-12
ALKERMES USD 456.48M 48.85M 2026-06
Alnylam Pharmaceuticals USD 912.74M 28.78M 2026-06
Amarin USD 126.83M 477K 2025-12
ANI Pharmaceuticals USD 274.47M 19.04M 2026-06
BioMarin Pharmaceutical USD 1.06B 157.13M 2026-06
Coherus Biosciences USD 18.42M 232.08M 2025-12
Emergent BioSolutions USD 290.1M 134.2M 2023-06
Exelixis USD 322.21M 6.73M 2026-06
Glaxosmithkline GBP 10.49B 40.6M 2026-03
Heron Therapeutics USD 89.59M 8.54M 2025-12
Ionis Pharmaceuticals USD 58.84M 15.16M 2026-06
Ironwood Pharmaceuticals USD 81.89M 5.68M 2024-12
Lexicon Pharmaceuticals USD 2.38M 50K 2025-12
Lonza CHF 1.78B 55M 2025-12
Merck USD 12.21B 435M 2026-03
Moderna USD 17M 54M 2026-06
Myriad Genetics USD 115.3M 2.7M 2025-12
Nektar Therapeutics USD 3.6M 1.82M 2026-03
Neurocrine Biosciences USD 887M 118.9M 2026-06
Pacira USD 132.42M 6.78M 2026-06
Pfizer USD 16.19B 19M 2026-06
PTC Therapeutics USD 219.92M 38.3M 2026-03
Sanofi EUR 492M 10M 2026-06
Sarepta Therapeutics USD 393.8M 154.11M 2026-06
United Therapeutics USD 310.3M 1.7M 2026-06
Vanda Pharmaceuticals USD 47.1M 4.35M 2024-12